Financhill
Sell
49

ZVRA Quote, Financials, Valuation and Earnings

Last price:
$9.37
Seasonality move :
37.31%
Day range:
$9.05 - $9.42
52-week range:
$4.20 - $9.76
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
11.28x
P/B ratio:
12.37x
Volume:
636.5K
Avg. volume:
608.9K
1-year change:
100%
Market cap:
$507.4M
Revenue:
$23.6M
EPS (TTM):
-$1.92

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ZVRA
Zevra Therapeutics
$17M -$0.18 405.53% -54.64% $21.71
DARE
Dare Bioscience
-- -$0.58 -100% -28.4% $13.00
GERN
Geron
$48.5M -$0.04 5212.1% -66.5% $3.69
MBRX
Moleculin Biotech
-- -- -- -- $9.33
MGNX
Macrogenics
$9.6M -$0.69 35.02% -15.36% $4.20
VYGR
Voyager Therapeutics
$13.6M -$0.44 -67.89% -190.56% $16.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ZVRA
Zevra Therapeutics
$9.28 $21.71 $507.4M -- $0.00 0% 11.28x
DARE
Dare Bioscience
$3.19 $13.00 $28.2M -- $0.00 0% 1,040.16x
GERN
Geron
$1.60 $3.69 $1B -- $0.00 0% 9.10x
MBRX
Moleculin Biotech
$0.66 $9.33 $9.4M -- $0.00 0% --
MGNX
Macrogenics
$1.78 $4.20 $112.3M -- $0.00 0% 0.73x
VYGR
Voyager Therapeutics
$3.46 $16.00 $191.5M 6.11x $0.00 0% 3.00x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ZVRA
Zevra Therapeutics
59.43% 1.664 14.67% 2.79x
DARE
Dare Bioscience
-- -0.774 -- 0.49x
GERN
Geron
30.68% 2.292 11.72% 6.84x
MBRX
Moleculin Biotech
-- 1.346 -- --
MGNX
Macrogenics
-- 1.321 -- 2.97x
VYGR
Voyager Therapeutics
-- 0.069 -- 5.92x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ZVRA
Zevra Therapeutics
$19.1M -$5.4M -89.91% -198.46% 0.26% -$8.3M
DARE
Dare Bioscience
$25.4K -$4.6M -- -- -18016.75% -$5.6M
GERN
Geron
$38.4M -$16.7M -35.11% -46.58% -29.38% -$48M
MBRX
Moleculin Biotech
-- -$5.9M -- -- -- -$4.6M
MGNX
Macrogenics
$7.8M -$42.6M -58.23% -58.23% -310.38% -$47.4M
VYGR
Voyager Therapeutics
-- -$34.7M -26.82% -26.82% -535.97% -$38.6M

Zevra Therapeutics vs. Competitors

  • Which has Higher Returns ZVRA or DARE?

    Dare Bioscience has a net margin of -15.19% compared to Zevra Therapeutics's net margin of -17219.13%. Zevra Therapeutics's return on equity of -198.46% beat Dare Bioscience's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ZVRA
    Zevra Therapeutics
    93.41% -$0.06 $101.1M
    DARE
    Dare Bioscience
    17.5% -$0.50 -$9.6M
  • What do Analysts Say About ZVRA or DARE?

    Zevra Therapeutics has a consensus price target of $21.71, signalling upside risk potential of 133.99%. On the other hand Dare Bioscience has an analysts' consensus of $13.00 which suggests that it could grow by 307.52%. Given that Dare Bioscience has higher upside potential than Zevra Therapeutics, analysts believe Dare Bioscience is more attractive than Zevra Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZVRA
    Zevra Therapeutics
    4 0 0
    DARE
    Dare Bioscience
    2 1 0
  • Is ZVRA or DARE More Risky?

    Zevra Therapeutics has a beta of 2.011, which suggesting that the stock is 101.078% more volatile than S&P 500. In comparison Dare Bioscience has a beta of 1.202, suggesting its more volatile than the S&P 500 by 20.169%.

  • Which is a Better Dividend Stock ZVRA or DARE?

    Zevra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dare Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics pays -- of its earnings as a dividend. Dare Bioscience pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ZVRA or DARE?

    Zevra Therapeutics quarterly revenues are $20.4M, which are larger than Dare Bioscience quarterly revenues of $25.4K. Zevra Therapeutics's net income of -$3.1M is higher than Dare Bioscience's net income of -$4.4M. Notably, Zevra Therapeutics's price-to-earnings ratio is -- while Dare Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics is 11.28x versus 1,040.16x for Dare Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZVRA
    Zevra Therapeutics
    11.28x -- $20.4M -$3.1M
    DARE
    Dare Bioscience
    1,040.16x -- $25.4K -$4.4M
  • Which has Higher Returns ZVRA or GERN?

    Geron has a net margin of -15.19% compared to Zevra Therapeutics's net margin of -50.09%. Zevra Therapeutics's return on equity of -198.46% beat Geron's return on equity of -46.58%.

    Company Gross Margin Earnings Per Share Invested Capital
    ZVRA
    Zevra Therapeutics
    93.41% -$0.06 $101.1M
    GERN
    Geron
    96.96% -$0.03 $387M
  • What do Analysts Say About ZVRA or GERN?

    Zevra Therapeutics has a consensus price target of $21.71, signalling upside risk potential of 133.99%. On the other hand Geron has an analysts' consensus of $3.69 which suggests that it could grow by 130.47%. Given that Zevra Therapeutics has higher upside potential than Geron, analysts believe Zevra Therapeutics is more attractive than Geron.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZVRA
    Zevra Therapeutics
    4 0 0
    GERN
    Geron
    4 3 0
  • Is ZVRA or GERN More Risky?

    Zevra Therapeutics has a beta of 2.011, which suggesting that the stock is 101.078% more volatile than S&P 500. In comparison Geron has a beta of 0.692, suggesting its less volatile than the S&P 500 by 30.798%.

  • Which is a Better Dividend Stock ZVRA or GERN?

    Zevra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics pays -- of its earnings as a dividend. Geron pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ZVRA or GERN?

    Zevra Therapeutics quarterly revenues are $20.4M, which are smaller than Geron quarterly revenues of $39.6M. Zevra Therapeutics's net income of -$3.1M is higher than Geron's net income of -$19.8M. Notably, Zevra Therapeutics's price-to-earnings ratio is -- while Geron's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics is 11.28x versus 9.10x for Geron. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZVRA
    Zevra Therapeutics
    11.28x -- $20.4M -$3.1M
    GERN
    Geron
    9.10x -- $39.6M -$19.8M
  • Which has Higher Returns ZVRA or MBRX?

    Moleculin Biotech has a net margin of -15.19% compared to Zevra Therapeutics's net margin of --. Zevra Therapeutics's return on equity of -198.46% beat Moleculin Biotech's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ZVRA
    Zevra Therapeutics
    93.41% -$0.06 $101.1M
    MBRX
    Moleculin Biotech
    -- -$0.69 --
  • What do Analysts Say About ZVRA or MBRX?

    Zevra Therapeutics has a consensus price target of $21.71, signalling upside risk potential of 133.99%. On the other hand Moleculin Biotech has an analysts' consensus of $9.33 which suggests that it could grow by 1309.87%. Given that Moleculin Biotech has higher upside potential than Zevra Therapeutics, analysts believe Moleculin Biotech is more attractive than Zevra Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZVRA
    Zevra Therapeutics
    4 0 0
    MBRX
    Moleculin Biotech
    0 0 0
  • Is ZVRA or MBRX More Risky?

    Zevra Therapeutics has a beta of 2.011, which suggesting that the stock is 101.078% more volatile than S&P 500. In comparison Moleculin Biotech has a beta of 1.562, suggesting its more volatile than the S&P 500 by 56.242%.

  • Which is a Better Dividend Stock ZVRA or MBRX?

    Zevra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moleculin Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics pays -- of its earnings as a dividend. Moleculin Biotech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ZVRA or MBRX?

    Zevra Therapeutics quarterly revenues are $20.4M, which are larger than Moleculin Biotech quarterly revenues of --. Zevra Therapeutics's net income of -$3.1M is higher than Moleculin Biotech's net income of -$6.4M. Notably, Zevra Therapeutics's price-to-earnings ratio is -- while Moleculin Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics is 11.28x versus -- for Moleculin Biotech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZVRA
    Zevra Therapeutics
    11.28x -- $20.4M -$3.1M
    MBRX
    Moleculin Biotech
    -- -- -- -$6.4M
  • Which has Higher Returns ZVRA or MGNX?

    Macrogenics has a net margin of -15.19% compared to Zevra Therapeutics's net margin of -311.07%. Zevra Therapeutics's return on equity of -198.46% beat Macrogenics's return on equity of -58.23%.

    Company Gross Margin Earnings Per Share Invested Capital
    ZVRA
    Zevra Therapeutics
    93.41% -$0.06 $101.1M
    MGNX
    Macrogenics
    59.07% -$0.65 $79.1M
  • What do Analysts Say About ZVRA or MGNX?

    Zevra Therapeutics has a consensus price target of $21.71, signalling upside risk potential of 133.99%. On the other hand Macrogenics has an analysts' consensus of $4.20 which suggests that it could grow by 135.96%. Given that Macrogenics has higher upside potential than Zevra Therapeutics, analysts believe Macrogenics is more attractive than Zevra Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZVRA
    Zevra Therapeutics
    4 0 0
    MGNX
    Macrogenics
    1 5 0
  • Is ZVRA or MGNX More Risky?

    Zevra Therapeutics has a beta of 2.011, which suggesting that the stock is 101.078% more volatile than S&P 500. In comparison Macrogenics has a beta of 1.652, suggesting its more volatile than the S&P 500 by 65.244%.

  • Which is a Better Dividend Stock ZVRA or MGNX?

    Zevra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Macrogenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics pays -- of its earnings as a dividend. Macrogenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ZVRA or MGNX?

    Zevra Therapeutics quarterly revenues are $20.4M, which are larger than Macrogenics quarterly revenues of $13.2M. Zevra Therapeutics's net income of -$3.1M is higher than Macrogenics's net income of -$41M. Notably, Zevra Therapeutics's price-to-earnings ratio is -- while Macrogenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics is 11.28x versus 0.73x for Macrogenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZVRA
    Zevra Therapeutics
    11.28x -- $20.4M -$3.1M
    MGNX
    Macrogenics
    0.73x -- $13.2M -$41M
  • Which has Higher Returns ZVRA or VYGR?

    Voyager Therapeutics has a net margin of -15.19% compared to Zevra Therapeutics's net margin of -479.24%. Zevra Therapeutics's return on equity of -198.46% beat Voyager Therapeutics's return on equity of -26.82%.

    Company Gross Margin Earnings Per Share Invested Capital
    ZVRA
    Zevra Therapeutics
    93.41% -$0.06 $101.1M
    VYGR
    Voyager Therapeutics
    -- -$0.53 $272.7M
  • What do Analysts Say About ZVRA or VYGR?

    Zevra Therapeutics has a consensus price target of $21.71, signalling upside risk potential of 133.99%. On the other hand Voyager Therapeutics has an analysts' consensus of $16.00 which suggests that it could grow by 356.01%. Given that Voyager Therapeutics has higher upside potential than Zevra Therapeutics, analysts believe Voyager Therapeutics is more attractive than Zevra Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZVRA
    Zevra Therapeutics
    4 0 0
    VYGR
    Voyager Therapeutics
    11 0 0
  • Is ZVRA or VYGR More Risky?

    Zevra Therapeutics has a beta of 2.011, which suggesting that the stock is 101.078% more volatile than S&P 500. In comparison Voyager Therapeutics has a beta of 0.820, suggesting its less volatile than the S&P 500 by 17.97%.

  • Which is a Better Dividend Stock ZVRA or VYGR?

    Zevra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Voyager Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics pays -- of its earnings as a dividend. Voyager Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ZVRA or VYGR?

    Zevra Therapeutics quarterly revenues are $20.4M, which are larger than Voyager Therapeutics quarterly revenues of $6.5M. Zevra Therapeutics's net income of -$3.1M is higher than Voyager Therapeutics's net income of -$31M. Notably, Zevra Therapeutics's price-to-earnings ratio is -- while Voyager Therapeutics's PE ratio is 6.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics is 11.28x versus 3.00x for Voyager Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZVRA
    Zevra Therapeutics
    11.28x -- $20.4M -$3.1M
    VYGR
    Voyager Therapeutics
    3.00x 6.11x $6.5M -$31M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Planet Labs’ Stock Go Next?
Where Will Planet Labs’ Stock Go Next?

On 4 June 2025 Planet reported Q1 FY 2026 revenue of $66.3 million, up 10% year over…

Where Will VICI Properties Be in 5 Years?
Where Will VICI Properties Be in 5 Years?

VICI Properties (NYSE:VICI) is a real estate investment trust focused…

Where Will Exxon Stock Be in 5 Years?
Where Will Exxon Stock Be in 5 Years?

For sure Exxon Mobil (NYSE: XOM) is no hyped-up AI…

Stock Ideas

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 49x

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 40x

Sell
43
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
75
INSM alert for Jun 11

Insmed [INSM] is up 7.75% over the past day.

Sell
25
AAON alert for Jun 11

AAON [AAON] is down 3.49% over the past day.

Buy
58
EXOD alert for Jun 11

Exodus Movement [EXOD] is down 8.21% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock